Darwin

Darwin EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Darwin (7V0.DE) as of Nov 5, 2026 is -9.03 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 17.24 % — a change of -152.37% (lower).

EBIT/Assets

-9.03 %

YoY

-152.37%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Darwin is 2025 -9.03 % . Operating Income to Assets Ratio (EBIT/Assets) of Darwin was 2024 17.24 % . It decreases by -152.37% lower compared to the previous year.

The Darwin EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2021
18.33 EUR
Jan 1, 2022
29.07 EUR
Jan 1, 2023
-2.09 EUR
Jan 1, 2024
17.24 EUR
Jan 1, 2025
-9.03 EUR
The Darwin EBIT/Assets history
YEAREBIT/AssetsYoY
-9.03 %-152.37%
17.24 %-923.86%
-2.09 %-107.20%
29.07 %+58.53%
18.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Darwin Stock analysis

What does Darwin do? Darwin AG generates revenue through the development and sale of dietary supplements and cosmetics products. The company leverages biotechnology and AI to create personalized solutions based on scientific lab analysis data. Its fully licensed laboratories offer genetic and metabolomic testing services, including lifestyle personal genomics and embryo screening during IVF to improve success rates. These services are provided to clients seeking personalized health and wellness solutions. The firm's products and services target individuals interested in personalized health, including those undergoing IVF treatments. The company's focus on genetic and metabolomic testing enables it to provide tailored recommendations for dietary supplements and cosmetics. This approach aligns with the growing demand for data-driven health and wellness products in the market. Darwin AG's business model integrates advanced biotechnology with AI to analyze genetic materials, which informs the development of its product lines. The company's fully licensed laboratories ensure compliance and quality in all testing services. Revenue streams are derived from both product sales and service-based offerings, catering to a segment of consumers prioritizing personalized health solutions. Darwin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Darwin stock

Operating Income to Assets Ratio (EBIT/Assets) of Darwin is -9.03 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Darwin changed from 17.24 % to -9.03 %, representing a -152.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Darwin since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Darwin with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Darwin

All Key Metrics — Darwin